Cell News and Research

RSS

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009

Caliper Life Sciences unveils XenoLight Rediject reagents series at WMIC

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced a series of XenoLight Rediject reagents at the World Molecular Imaging Congress (WMIC) in Montreal, Canada. Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents for Caliper's IVIS optical imaging systems.

25 Sep 2009

Researchers develop a process to tag cancer cells

Scientists label cells with coloured or glowing chemicals to observe how basic cellular activities differ between healthy and cancerous cells. Existing techniques for labelling cells are either too slow or too toxic to perform on live cells. Now, a study reviewed by Philip Dawson, a member of Faculty of 1000 Biology and leading authority in chemistry and cell biology, describes a novel labelling technique that uses a chemical reaction to make live cancer cells light up quickly and safely.

25 Sep 2009

Collaboration for the evaluation of peptide copolymer technology

Peptimmune, Inc., a privately held biotechnology company announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEP(TM) peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics.

25 Sep 2009

Huachansu may slow cancer progression

Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

25 Sep 2009

Moderately elevated levels of ROS positive in fruit flies

It has been known for decades that reactive oxygen species (ROS) - ions or very small molecules that include free radicals - damage cells. But much to their surprise, Jonsson Cancer Center researchers found that in Drosophila, the common fruit fly, moderately elevated levels of ROS are a good thing.

25 Sep 2009

Tooth cell banking for the treatment of future diseases

Pioneered by BioEDEN, tooth cell banking is a safe, natural and wholly non-invasive method of collecting and preserving precious stem cells which could hold the key to children's health.

25 Sep 2009

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.

25 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

Researchers study functional similarity between zebrafish and humans to fight infections

Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms. Zebrafish are becoming an important model for human disease, since they are easily handled, maintained and manipulated and many fundamental processes between zebrafish and humans are conserved.

24 Sep 2009

Mandell, Douglas, and Bennett's publication on infectious diseases released

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition. Marking 30 years since its initial publication, it remains the most respected reference source of its kind, and maintains its relevance in the face of the emergence of newly recognized infectious diseases, including new strains of the swine (H1N1) and avian influenza viruses.

24 Sep 2009

Opexa Therapeutics' endeavor in the field of stem cell technology

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company’s recently announced exclusive stem cell agreement with Novartis, one of the world’s largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

24 Sep 2009

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.

24 Sep 2009

Pre-clinical data demonstrates advantages of Combo Stent

OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Research to identify inborn genetic susceptibility to colon cancer metastasis

A prestigious National Institutes of Health (NIH) Transformative R01 Program grant for $4.9 million has been awarded to Case Western Reserve University School of Medicine. The five-year grant will fund research to identify patients' inborn genetic susceptibility to the development of colon cancer metastasis. Case Western Reserve was one of only 42 recipients of this competitive new grant designed to support exceptionally innovative, high risk, original and/or unconventional research projects that have the potential to create or overturn fundamental paradigms.

24 Sep 2009

NIH awards three UNC Scientists for high risk and innovative research

Three scientists from the University of North Carolina at Chapel Hill School of Medicine and the UNC Lineberger Comprehensive Cancer Center have received prestigious awards from the National Institutes of Health (NIH) aimed at encouraging "high risk" and innovative research.

24 Sep 2009

New software to be demonstrated at the International CTIA WIRELESS IT & Entertainment 2009

AuthenTec, the world’s leading provider of smart sensor based solutions, announced that it will demonstrate its newest mobile products and software, and will highlight new commercially released phones that incorporate its award-winning technology at International CTIA WIRELESS IT & Entertainment 2009 in San Diego.

24 Sep 2009

How the human brain processes incoming sensory signals amidst background noise

The brain never sits idle. Whether we are awake or asleep, watch TV or close our eyes, waves of spontaneous nerve signals wash through our brains. Researchers at the Salk Institute for Biological Studies studying visual attention have discovered a novel mechanism that explains how incoming sensory signals make themselves heard amidst the constant background rumblings so they can be reliably processed and passed on.

24 Sep 2009

Phase II study of OPAXIO to be revealed

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

24 Sep 2009